Table 1.

Patient Characteristics by Treatment Group

Characteristic	No. (%) of Patients
	Doxorubicin Alone (n = 264)	Doxorubicin + Dexrazoxane (n = 273)	Total (N = 537)
Mean (SD) age, years	9.7 (4.58)	9.9 (4.90)	9.8 (4.74)
Median (range) follow-up, years	8.9 (0.02-14.7)	9.4 (0.01-15.0)	9.2 (0.01-15.0)
Male sex	203 (76.9)	204 (74.7)	407 (75.8)
Ethnicity
White	170 (64.4)	186 (68.1)	356 (66.3)
Nonwhite	94 (35.6)	87 (31.9)	181 (33.7)
T-ALL subset
Median (range) follow-up, years	9.0 (0.02-14.7)	9.3 (0.01-14.5)	9.1 (0.01-14.7)
WBC, × 1,000/μL
< 50	71	84	155
≥ 50	104	103	207
CNS positive (CNS2/3/bloody tap)	44	56	100
L-NHL subset
Median (range) follow-up, years	8.5 (0.4-13.9)	9.5 (0.2-15.0)	9.2 (0.2-15.0)
With stage III disease	67	52	119
With stage IV disease	22	33	55
With echocardiogram data*†
Total No. of patients with echocardiograms at least one time point	218	224	442
Median (min, max) No. of echocardiograms per patient	3 (1, 10)	3 (1, 13)	3 (1, 13)
Total No. of patients with echocardiograms at each time point
Baseline	158	149	307
Approximately week 34	61	82	143
3 years	84	83	167
3.5 to 6.5 years	21	31	52
With troponin data*
Total No. of patients with at least one troponin measurement	114	125	239
Median (min, max) No. of samples per patient	1 (1, 6)	1 (1, 6)	1 (1, 6)
Total No. of troponin measures per patient
1	78 (68.4)	69 (55.2)	147 (61.5)
2	21 (18.4)	34 (27.2)	55 (23.0)
3	10 (8.8)	16 (12.8)	26 (10.9)
4	3 (2.6)	4 (3.2)	7 (2.9)
5	1 (0.9)	1 (0.8)	2 (0.8)
6	1 (0.9)	1 (0.8)	2 (0.8)

Abbreviations: L-NHL, lymphoblastic non-Hodgkin lymphoma; SD, standard deviation; T-ALL, T-cell acute lymphoblastic leukemia.

^*Additional comparisons in Appendix Tables A1 through A4, online only.

^†For those patients with more than one echocardiogram for a particular time point, the later one was used as the data for that time point.